JAK2 and laryngeal carcinoma: Brusatol (Zhou et al., 2021) reversed the Hep-2 cell epithelial-mesenchymal transition (EMT) process, abolishing the Janus kinase 2 (JAK2)/STAT3 signaling pathway in laryngeal cancer cell line.